Oak Harvest Investment Services Has $2.28 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Oak Harvest Investment Services grew its position in Zoetis Inc. (NYSE:ZTSFree Report) by 16.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,685 shares of the company’s stock after purchasing an additional 1,681 shares during the period. Oak Harvest Investment Services’ holdings in Zoetis were worth $2,283,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Sarasin & Partners LLP lifted its position in Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares in the last quarter. Swedbank AB bought a new stake in Zoetis during the 1st quarter worth about $210,815,000. International Assets Investment Management LLC raised its holdings in Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the last quarter. Marshall Wace LLP raised its holdings in Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after purchasing an additional 824,843 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after purchasing an additional 414,605 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.8 %

NYSE:ZTS opened at $182.78 on Thursday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The business has a 50 day moving average price of $189.02 and a two-hundred day moving average price of $178.28. The company has a market cap of $82.81 billion, a P/E ratio of 35.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.41 EPS. As a group, analysts expect that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 33.14%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Piper Sandler boosted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. BTIG Research upped their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $221.44.

Check Out Our Latest Analysis on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.